Ironclad’s Post

Nothing but respect to Paul O'Donoghue and Jonathan Jones for the recent podcast they did on Give N Toke. Along with the quote that is shown in the image, there were several other critical points that brought to question the quality of product that is produced in Australia. Some may think that comments, like this quote, from Jonathan Jones are damaging to the local industry. My take is that this is about making statements to level-up the industry, which if achieved will result in a net-positive for everyone. #ontracka #research #safeprescribing #rwd #clinicaltrials #pharmacovigilience #medtech #ai #realworldevidence #clinicalresearch

Has AI changed the course of drug development? https://lnkd.in/eTH_FHQ2 NotebookLM turned my post to a podcast https://lnkd.in/e2TM6dax

The emergence of Artificial Intelligence (AI) in society in recent years has given us a glimpse into the future - but how does it help us monitor and learn more about our ocean? Professor Sara Bernardini and Dr Fatma Jebri tell us more about the use of AI in oceanography and how they see it progressing in the future. The latest story relates to how the National Oceanography Centre (NOC) has developed a new AI-enabled approach to test for toxic algae that can result in severe and fatal sickness in humans. #ai #algae #toxicology

Food must be proven to be safe before being allowed into the marketplace #fda #efsa ; pharmaceuticals must be proven to be safe before being allowed into the marketplace #fda #ema. The case against regulation of #ai in any of its current or future manifestations is built on sand and flies in the face of common sense. Surely the burden of proof is not on us to prove #ai is dangerous, but on developers to prove it is safe? How much effort would be required to create national red team agencies to verify developer claims (a rhetorical question) before allowing their products into the marketplace? We need to revive The Pause. https://lnkd.in/ePEh5e8B

AI is transforming clinical writing in pharma, accelerating FDA approvals and market entry. In this episode of Biotech Bytes, Amar Drawid, Ph.D., Chief AI & Business Consulting Officer at Agilisium Consulting, discusses how automating clinical writing saves time and resources. listen to the full episode: https://lnkd.in/eBMYMYSv Thanks to Biotech Bytes, The Swan Group, and host Steven Swan for the collaboration! Key highlights: ☑️ Automating clinical writing for faster FDA approvals. ☑️ Measuring ROI through time savings. ☑️ Integrating business and tech for AI success.

A few days ago, I was a guest in the Biotech Bytes podcast. I had an insightful conversation with Steven Swan from The Swan Group, where we discussed my generative AI framework for Life Science use cases and the current trends in automating clinical writing, a significant demand area aimed at reducing the time spent on drafting documentation for FDA submissions. I shared some insights on how rapid first drafts can lead to quicker FDA approvals and faster market entry for drugs. We also tackle how to measure the return on investment for these innovations. Tune in to learn more. 👉  https://lnkd.in/eTkqCci2 Agilisium Consulting #podcast #biotech #AI #clinicalwriting #clinicaltrials #FDAapprovals #FDAsubmissions

One the best explanations I have heard on how #MachineLearning, and #AI can be used with systems biology to increase cycle speed and efficiency in #drugdesign. Well worth listening to Philip Tagari’s podcast with Vijay Pande, PhD .

"If you trust AI to drive your car or talk to you in your home - why wouldn't you trust them to learn chemistry?" This week I connected with Deloitte's Daniel Ferrante, Ph.D., who helps to lead Deloitte's Atlas AI for drug discovery. The question above is his. And it's a good question, frankly. Even at the cutting edge, AI adoption hinges as much on change management as it does on the nuances of data science. He talks through some of the crucial change management aspects of getting data science right, the importance of data accessibility for drug discovery efforts, and how genAI might help drug discovery leaders access a wider range of information to predicting drug-to-protein binding and develop new pharmaceuticals. [The link to this episode - for Spotify and Apple Podcasts - is in the top comment]

On this last episode of the Biotech Bytes Podcast, Steve was joined by Rajvir (Raj) Madan, Chief Digital and Technology Officer at Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), where we break down the transformative impact AI is having in our field. Their discussion spans from the reduction of drug discovery timelines to addressing ethical concerns related to data biases. We also confront challenges tied to data quality and the implications for the workforce in the era of AI. To grasp the full spectrum of AI's influence on biotech and the vision it's charting for our future, tune in for a compelling episode. 👉 https://buff.ly/498iEgq #podcast #pharma #biotech #databiases #dataquality #data #ai #technology #IT

#podcast Amy Brown, CEO of Authenticx, uses conversational intelligence to analyze conversations between humans and between humans and chatbots to gain insights that can drive improvements in patient experience, operational efficiency, and faster resolution of problems in the healthcare environment. Using AI and trained professionals, the Authenticx solution helps pharmaceutical companies improve drug launches, personalize customer interactions and respond more effectively to patient needs. In clinical situations, the machine learning models help identify and address obstacles. #Authenticx #ListeningWithAI #ConversationalIntelligence #PatientExperience #AIinHealthcare Authenticx.com https://lnkd.in/guqBeiP5